Thursday, 22nd​ September h. 11.30 – 12.45 (CET)

Parallel session

Hot issues in the pharmaceutical sector: between regulation and competition

Managed by Fréget Glaser & Associés

Fréget Glaser & Associés

After focusing over the last 10-15 years mainly on pay-for-delay cases, EU and national antitrust authorities are increasingly shifting their scrutiny to a broader range of practices, including disparagement, ‘legally unfounded interventions’, excessive pricing. While some of these continue to deal with fair access to market by generics, others raise questions about handling information submitted to health regulators or other public authorities, what is a ‘fair price’ and who should determine it.